Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeted inversion and reversion of the blood coagulation factor 8 gene in human iPS cells using TALENs

9 Jun 2014

Abstract excerpt

Hemophilia A, one of the most common genetic bleeding disorders, is caused by various mutations in the blood coagulation factor VIII (F8) gene. Among the genotypes that result in hemophilia A, two different types of chromosomal inversions that involve a portion of the F8 gene are most frequent, accounting for almost half of all severe hemophilia A cases. In this study, we used a transcription activator-like...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related gene regulation
Share to CRISPR and Genetic Engineering
Share to Hemophilia Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24927536
DOI: 10.1073/pnas.1323941111

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeted inversion and reversion of the blood coagulation factor 8 gene in human iPS cells using TALENsPMID 24927536Read ↗

In situ genetic correction of F8 intron 22 inversion in hemophilia A patient-specific iPSCsSemantic proximity Read ↗

Restoration of FVIII Function and Phenotypic Rescue in Hemophilia A Mice by Transplantation of MSCs Derived From F8-Modified iPSCsSemantic proximity Read ↗

ssODN-Mediated In-Frame Deletion with CRISPR/Cas9 Restores FVIII Function in Hemophilia A-Patient-Derived iPSCs and ECsSemantic proximity Read ↗

Modeling and correction of structural variations in patient-derived iPSCs using CRISPR/Cas9.Semantic proximity Read ↗

Genetic Correction and Hepatic Differentiation of Hemophilia B-specific Human Induced Pluripotent Stem Cells.Semantic proximity Read ↗

Correction of a Factor VIII genomic inversion with designer-recombinasesSemantic proximity Read ↗

Generation of induced pluripotent stem cell, BCHSCTi001-A, derived from a Hemophilia A patient with F8 (p. R391C) mutation.Semantic proximity Read ↗

Generation of iPSC line from urine cells of hemophilia A with F8 (p. R814X) mutation.Semantic proximity Read ↗

Genome Editing of Structural Variations: Modeling and Gene Correction.Semantic proximity Read ↗

CRISPR/Cas9-Mediated in vivo Genetic Correction in a Mouse Model of Hemophilia ASemantic proximity Read ↗

Generation of an mESC model with a human hemophilia B nonsense mutation via CRISPR/Cas9 technology.Semantic proximity Read ↗

Long-term correction of hemophilia A via integration of a functionally enhanced FVIII gene into the AAVS1 locus by nickase in patient-derived iPSCsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.